The first 60 days: Oesophageal cancer
Oesophageal cancer is really two diseases sharing one organ: squamous cell carcinoma, which dominates in Asia, and adenocarcinoma, which dominates in the West and is treated like gastric cancer. Immunotherapy is now standard, and the bispecific ADC iza-bren posted a positive phase 3 in the squamous type in 2026. Below, week by week, is what OnCo's record of Oesophageal cancer says about the first two months: the order is typical, the timing is yours to ask about. Sections appear only where the record has something to say. Orientation, not medical advice.
What happens now
Staging tests establish exactly what and where the cancer is. Everything else follows from the answers.
Ask which of these were tested and what the results were; see the report reader for what each value means.
These specialties appear in the standard of care for this cancer. In most centres they meet weekly as a tumour board to agree each plan; you can ask when yours was discussed and what was decided.
- PathologistNamed in the standard of care for: Clinical complete response after chemoradiation, Advanced adenocarcinoma, first line.
- RadiologistNamed in the standard of care for: Clinical complete response after chemoradiation.
- SurgeonNamed in the standard of care for: Localised, Prevention and screening, Early (T1a, high-grade dysplasia), Resectable locally advanced (cT2-4a or N+) and 1 more.
- Medical oncologistNamed in the standard of care for: Localised, Advanced, Resectable locally advanced (cT2-4a or N+), Unresectable locally advanced or cervical and 5 more.
- Clinical oncologist (radiotherapy)Named in the standard of care for: Localised, Resectable locally advanced (cT2-4a or N+), Unresectable locally advanced or cervical, Palliation of dysphagia.
- Palliative and supportive care teamNamed in the standard of care for: Palliation of dysphagia.
A second opinion from a centre that treats many similar cases is normal, not rude; the standard of care tells you what to compare it against.
Each row is a setting from the standard of care, in the order it usually arises. Not all will apply to you; your stage and biomarkers decide which do. The guideline grade, where recorded, says how strong the evidence is.
Tobacco and alcohol control; endoscopic screening of high-risk populations in China and Japan (Lugol chromoendoscopy); surveillance of Barrett's oesophagus with ablation or resection of dysplasia; non-endoscopic capsule-sponge screening in trials (BEST4).
Neoadjuvant chemoradiation (CROSS) or perioperative FLOT → surgery → nivolumab if residual disease.
Endoscopic resection (EMR/ESD) with radiofrequency ablation of residual Barrett's; oesophagectomy for T1b with high-risk features.
- 4.Resectable locally advanced (cT2-4a or N+)NCCN category Category 1 (preoperative chemoradiation; adjuvant nivolumab)
CROSS chemoradiation (carboplatin/paclitaxel + 41.4 Gy) then oesophagectomy for squamous and adenocarcinoma; perioperative FLOT for adenocarcinoma/GEJ (ESOPEC). Adjuvant nivolumab for residual disease after chemoradiation (CheckMate 577).
Definitive chemoradiation (50-50.4 Gy with cisplatin/5-FU or carboplatin/paclitaxel); PD-1 blockade added in trials.
Chemotherapy + pembrolizumab/nivolumab; iza-bren in trials.
Active surveillance with surgery on regrowth is a non-inferior option (SANO); requires intensive endoscopic and PET surveillance.
Chemotherapy + pembrolizumab (KEYNOTE-590), nivolumab (CheckMate 648), or tislelizumab (RATIONALE-306, PD-L1 ≥1%); nivolumab + ipilimumab chemotherapy-free option; camrelizumab/sintilimab/toripalimab in China.
As for gastric cancer: chemotherapy + pembrolizumab or nivolumab (PD-L1 CPS ≥5 or ≥1); trastuzumab-based therapy if HER2-positive; zolbetuximab if CLDN18.2-positive (GEJ eligible in SPOTLIGHT/GLOW).
Self-expanding metal stent, brachytherapy, or external beam radiation; nutritional support; early palliative care.
Izalontamab brengitecan after PD-(L)1 + platinum (PANKU-Esophagus01, OS and PFS benefit, 2026; approval pending); otherwise taxane or irinotecan; nivolumab/pembrolizumab if IO-naive.
T-DXd if HER2-positive (DESTINY-Gastric04); ramucirumab + paclitaxel; CLDN18.2 ADC after CLARITY-Gastric 01.
Generated from this cancer's standard of care, biomarkers and open problems. Take the group that matches where you are. To tick, add your own and print, open the one-page appointment sheet.
Newly diagnosed
- What is my exact diagnosis, stage, and grade, and which tests established them?Everything else follows from an accurate stage and subtype.
- Which biomarkers have been tested on my tumour (for example PD-L1, HER2, EGFR, Histologydetermines the pathway, PD-L1), and what were the results?These results decide eligibility for targeted therapy, immunotherapy, and trials.
- Which subtype is my cancer, and does that change the recommended treatment?Recognised subtypes for this cancer include Squamous cell carcinoma, Adenocarcinoma, GEJ tumours by Siewert type.
- Is germline (inherited) genetic testing recommended for me or my family?Inherited variants can change treatment and matter for relatives.
Localised
- For my situation (localised), which of the standard options do you recommend and why?Guideline options include: Neoadjuvant chemoradiation (CROSS) or perioperative FLOT → surgery → nivolumab if residual disease.
- Am I a candidate for Nivolumab, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
Advanced
- For my situation (advanced), which of the standard options do you recommend and why?Guideline options include: Chemotherapy + pembrolizumab/nivolumab; iza-bren in trials.
- Am I a candidate for Pembrolizumab, Izalontamab brengitecan, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
Prevention and screening
- For my situation (prevention and screening), which of the standard options do you recommend and why?Guideline options include: Tobacco and alcohol control; endoscopic screening of high-risk populations in China and Japan (Lugol chromoendoscopy); surveillance of Barrett's oesophagus with ablation or resection of dysplasia; non-endoscopic capsule-sponge screening in trials (BEST4).
Early (T1a, high-grade dysplasia)
- For my situation (early (t1a, high-grade dysplasia)), which of the standard options do you recommend and why?Guideline options include: Endoscopic resection (EMR/ESD) with radiofrequency ablation of residual Barrett's; oesophagectomy for T1b with high-risk features.
Resectable locally advanced (cT2-4a or N+)
- For my situation (resectable locally advanced (ct2-4a or n+)), which of the standard options do you recommend and why?Guideline options include: CROSS chemoradiation (carboplatin/paclitaxel + 41.4 Gy) then oesophagectomy for squamous and adenocarcinoma; perioperative FLOT for adenocarcinoma/GEJ (ESOPEC). Adjuvant nivolumab for residual disease after chemoradiation (CheckMate 577).
- Am I a candidate for FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), Nivolumab, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of CROSS and CheckMate 577 apply to someone like me?Trial populations differ from individual patients; ask how closely you match.
Clinical complete response after chemoradiation
- For my situation (clinical complete response after chemoradiation), which of the standard options do you recommend and why?Guideline options include: Active surveillance with surgery on regrowth is a non-inferior option (SANO); requires intensive endoscopic and PET surveillance.
- How do the results of SANO apply to someone like me?Trial populations differ from individual patients; ask how closely you match.
Unresectable locally advanced or cervical
- For my situation (unresectable locally advanced or cervical), which of the standard options do you recommend and why?Guideline options include: Definitive chemoradiation (50-50.4 Gy with cisplatin/5-FU or carboplatin/paclitaxel); PD-1 blockade added in trials.
Advanced squamous cell carcinoma, first line
- For my situation (advanced squamous cell carcinoma, first line), which of the standard options do you recommend and why?Guideline options include: Chemotherapy + pembrolizumab (KEYNOTE-590), nivolumab (CheckMate 648), or tislelizumab (RATIONALE-306, PD-L1 ≥1%); nivolumab + ipilimumab chemotherapy-free option; camrelizumab/sintilimab/toripalimab in China.
- Am I a candidate for Pembrolizumab, Nivolumab, Ipilimumab or related drugs, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of KEYNOTE-590 and CheckMate 648 apply to someone like me?Trial populations differ from individual patients; ask how closely you match.
Advanced adenocarcinoma, first line
- For my situation (advanced adenocarcinoma, first line), which of the standard options do you recommend and why?Guideline options include: As for gastric cancer: chemotherapy + pembrolizumab or nivolumab (PD-L1 CPS ≥5 or ≥1); trastuzumab-based therapy if HER2-positive; zolbetuximab if CLDN18.2-positive (GEJ eligible in SPOTLIGHT/GLOW).
- Am I a candidate for Trastuzumab, Zanidatamab, Zolbetuximab, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of KEYNOTE-590 and CheckMate 649 apply to someone like me?Trial populations differ from individual patients; ask how closely you match.
Second line, squamous cell carcinoma
- For my situation (second line, squamous cell carcinoma), which of the standard options do you recommend and why?Guideline options include: Izalontamab brengitecan after PD-(L)1 + platinum (PANKU-Esophagus01, OS and PFS benefit, 2026; approval pending); otherwise taxane or irinotecan; nivolumab/pembrolizumab if IO-naive.
- Am I a candidate for Izalontamab brengitecan, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of PANKU-Esophagus01 (BL-B01D1-305) apply to someone like me?Trial populations differ from individual patients; ask how closely you match.
Second line, adenocarcinoma
- For my situation (second line, adenocarcinoma), which of the standard options do you recommend and why?Guideline options include: T-DXd if HER2-positive (DESTINY-Gastric04); ramucirumab + paclitaxel; CLDN18.2 ADC after CLARITY-Gastric 01.
- Am I a candidate for Trastuzumab deruxtecan, Ramucirumab, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of DESTINY-Gastric04 and CLARITY-Gastric 01 apply to someone like me?Trial populations differ from individual patients; ask how closely you match.
Palliation of dysphagia
- For my situation (palliation of dysphagia), which of the standard options do you recommend and why?Guideline options include: Self-expanding metal stent, brachytherapy, or external beam radiation; nutritional support; early palliative care.
Any stage
- Are there clinical trials I could join, for example of Izalontamab brengitecan, PF-08634404, HS-20093, QLC5508?Trials are how the next standard of care is set; asking early keeps options open.
- Would a second opinion at a high-volume centre change anything, and can you help arrange it?Rare or high-stakes decisions benefit from a centre that treats many similar patients.
- What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?Supportive care improves quality of life and helps patients complete treatment.
- I read that “Late presentation”. How does that affect my plan?Open problems are where trials and second opinions matter most.
- I read that “Squamous cell carcinoma lacks targets beyond EGFR/HER3”. How does that affect my plan?Open problems are where trials and second opinions matter most.
Trials open now for this cancer in OnCo, largest phase first. Joining a trial is a decision like any other: ask what the comparison arm is, whether a placebo is used, and what happens if you leave. The cancer page searches ClinicalTrials.gov live for more.
- A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)Phase 3 · recruiting · NCT06644781A Phase 3, Multicenter, Randomized, Open-label Study of Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
- A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal CancerPhase 3 · recruiting · NCT06194734A Randomized, Controlled, Open-label, Multicenter Phase III Study to Evaluate the Efficacy and Safety of KC1036 Versus Investigator's Choice of Chemotherapy as Third-line Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma
- A Study to Compare the Efficacy and Safety of LY01015 and Opdivo® Combined Respectively With Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell CarcinomaPhase 3 · recruiting · NCT06022861A Randomized, Double-blind, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of LY01015 and Opdivo®（Nivolumab Injection）Combined Respectively With Fluorouracil Plus Cisplatin in Participants With Advanced or Metastatic Esophageal Squamous Cell Carcinoma.
- A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)Phase 3 · active · NCT06356311A Phase 3, Multicenter, Open-label, Randomized Study to Compare the Efficacy and Safety of MK-2870 Versus Treatment of Physician's Choice in 3L+ Advanced/Metastatic Gastroesophageal Adenocarcinoma (Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, and Esophageal Adenocarcinoma)
- Add-AspirinPhase 3 · active · NCT02804815After curative treatment for breast, colorectal, gastro-oesophageal or prostate cancer: aspirin 100 mg vs 300 mg vs placebo daily for 5 years
Much of what helps in the first weeks is free if you know to ask: testing, helplines, rides and lodging, second opinions, trial travel.
- Oesophageal cancer: the full pageOesophageal cancer is really two diseases sharing one organ: squamous cell carcinoma, which dominates in Asia, and adenocarcinoma, which dominates in the West and is treated like gastric cancer. Immunotherapy is now standard, and the bispecific ADC iza-bren posted a positive phase 3 in the squamous type in 2026.
- One-page appointment sheetYour questions, the words you may hear, what to bring, and space for the answers. Print it.
- Guidelines comparedNCCN, ESMO and NICE side by side for this cancer.
- Treatment sequencingWhich treatment tends to follow which, line by line.
- NavigatorStandard of care for your stage, what you have tried, and trials near you.
- Barrett's oesophagus: A change in the lining of the lower oesophagus caused by acid reflux that can, in a minority, progress through dysplasia to adenocarcinoma.
- Squamous cell carcinoma vs adenocarcinoma of the oesophagus: Oesophageal cancer is two different diseases in one organ: squamous cell carcinoma (upper/mid oesophagus, tobacco and alcohol, dominant in Asia) and adenocarcinoma (lower oesophagus, reflux and obesity, dominant in the West).
- FLOT regimen (perioperative chemotherapy for gastric cancer): Four cycles of chemotherapy before and four after surgery for stomach and junction cancer, using fluorouracil, leucovorin, oxaliplatin and docetaxel.
- Oesophagectomy: Surgery that removes most of the food pipe (oesophagus) and rebuilds it by pulling the stomach up into the chest.
- Dysphagia (difficulty swallowing): Trouble swallowing, either because a tumour narrows the food pipe or throat, or because radiotherapy and surgery to the head, neck or chest have damaged the muscles and nerves that coordinate swallowing.
- Gastrectomy: Removing part (subtotal) or all (total) of the stomach for stomach cancer, with the bowel joined to what remains.
- Gastro-oesophageal junction (GEJ): Where the food pipe meets the stomach.
- Feeding tube (gastrostomy, PEG, jejunostomy): A tube placed into the stomach (gastrostomy, PEG) or small bowel (jejunostomy) so a patient who cannot swallow enough can still be fed through the gut.
- Mediastinum: The space in the middle of the chest between the two lungs, containing the heart, great vessels, windpipe, food pipe and the lymph nodes that lung cancer spreads to first.
- Siewert classification (GEJ tumours): A way of classifying cancers at the junction of the oesophagus and stomach by where their centre sits, which decides whether they are treated as oesophageal or gastric.
Every term links to the glossary.